Difference between revisions of "Editing test page 2"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Replaced content with " Category:Null pages") |
|||
| Line 1: | Line 1: | ||
| + | ==TCHP (Taxotere) {{#subobject:14bd42|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | TCHP: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''arboplatin, '''<u>H</u>'''erceptin (Trastuzumab), '''<u>P</u>'''ertuzumab | ||
| + | ===Regimen {{#subobject:34a874|Variant=1}}=== | ||
| + | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| + | !Study | ||
| + | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !Comparator | ||
| + | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
| + | |- | ||
| + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)] | ||
| + | |style="background-color:#1a9851"|Phase III | ||
| + | |[[#TCH_.28Taxotere.2C_Carboplatin.29|TCH]] | ||
| + | |style="background-color:#91cf60"|Seems to have superior invasive DFS | ||
| + | |- | ||
| + | |} | ||
| + | ====Preceding treatment==== | ||
| + | *Surgery | ||
| + | ====Chemotherapy==== | ||
| + | *[[Docetaxel (Taxotere)]] as follows: | ||
| + | **Cycles 1 to 6: 75 mg/m<sup>2</sup> IV once on day 1 | ||
| + | *[[Carboplatin (Paraplatin)]] as follows: | ||
| + | **Cycles 1 to 6: AUC 6 (maximum dose: 900 mg) IV once on day 1 | ||
| + | *[[Trastuzumab (Herceptin)]] as follows: | ||
| + | **Cycle 1: 8 mg/kg IV once on day 1 | ||
| + | **Cycle 2 onwards: 6 mg/kg IV once on day 1 | ||
| + | *[[Pertuzumab (Perjeta)]] as follows: | ||
| + | **Cycle 1: 840 mg IV once on day 1 | ||
| + | **Cycle 2 onwards: 420 mg IV once on day 1 | ||
| + | |||
| + | '''21-day cycle for up to 1 year of therapy (18 doses of trastuzumab & pertuzumab)''' | ||
| + | |||
| + | ===References=== | ||
| + | # von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [http://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed] | ||
[[Category:Null pages]] | [[Category:Null pages]] | ||
Revision as of 13:15, 8 February 2018
TCHP (Taxotere)
| back to top |
TCHP: Taxotere (Docetaxel), Carboplatin, Herceptin (Trastuzumab), Pertuzumab
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| von Minckwitz et al. 2017 (APHINITY) | Phase III | TCH | Seems to have superior invasive DFS |
Preceding treatment
- Surgery
Chemotherapy
- Docetaxel (Taxotere) as follows:
- Cycles 1 to 6: 75 mg/m2 IV once on day 1
- Carboplatin (Paraplatin) as follows:
- Cycles 1 to 6: AUC 6 (maximum dose: 900 mg) IV once on day 1
- Trastuzumab (Herceptin) as follows:
- Cycle 1: 8 mg/kg IV once on day 1
- Cycle 2 onwards: 6 mg/kg IV once on day 1
- Pertuzumab (Perjeta) as follows:
- Cycle 1: 840 mg IV once on day 1
- Cycle 2 onwards: 420 mg IV once on day 1
21-day cycle for up to 1 year of therapy (18 doses of trastuzumab & pertuzumab)
References
- von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. link to original article link to supplementary protocol contains verified protocol in supplementary protocol link to PMC article PubMed